Tag Archives: Bristol Myers Squibb

Patient Adherence Awards Winners Revealed

Image via Wikipedia The Center for Business Intelligence, on Monday, revealed winners of its annual Strategic Patient Adherence Awards as part of its two-day conference about patient compliance with their drug regiments. This year’s award winners are: Best Integrated Program—Shire Pharmaceuticals: FOSRENOL ON TRACK Direct To Patient Support Program Best Disease State Program—BMS/Sanofi-Aventis Canada & […]
Posted in Events, Strategy | Also tagged , , , , , , , , | Leave a comment

AstraZeneca, BMS Announce Layoffs and Buyouts

AstraZeneca was the topic of conversation this week as word broke that the company is offering buyout deals to every member of its 5,500 US sales force. “AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they […]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment

Judge Throws The Book At Former Bristol-Myers Squibb Exec

Media wordsmiths are competing to outdo one another today in punny reporting on the news that ex-BMS exec Andrew Bodnar has been sentenced to write a book about the role he played in the firm’s 2006 reverse-payments case over generic Plavix. “Pen-ance: Bristol-Myers Exec Gets Two Years of Hard Writing,” The Wall Street Journal Law […]
Posted in Legal | Also tagged , , , , , , , | Leave a comment

Gilead Making a Bundle

Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech […]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment

Lilly Puts Up $6.5 Billion for ImClone

Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. […]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta